Stelzer K J
Department of Radiation Oncology, University of Washington Medical Center, Seattle 98195-6043, USA.
Neurosurg Clin N Am. 2000 Oct;11(4):597-604.
Acute toxicity from radiation of skull base tumors typically resolves spontaneously within days to weeks after completion of therapy. Long-term complications have a latency of months to years after radiation and are usually irreversible. The need to keep the probability of chronic toxicity at an acceptable level has determined the upper limits of radiation doses for the treatment of tumors. The threat of chronic toxicity thus affects the ability to control skull base tumors with radiation. Use of conformal radiation techniques with image guidance, allowing minimization of normal tissue volume receiving significant radiation doses and close regulation of doses to specific structures, provides a low probability of long-term complications. Such conformal techniques may result in improved tumor control by allowing delivery of higher radiation doses to the tumor while maintaining an acceptable level of risk for chronic toxicity. Symptoms resulting from chronic radiation toxicity are indistinguishable from those due to tumor progression. In most cases in which radiation is used to treat tumors throughout the body, symptoms developing months after radiation are secondary to tumor recurrence and not due to toxicity from radiation. Notable exceptions are pituitary hormonal dysfunction after radiation for pituitary adenoma and cranial neuropathy after radiosurgery for vestibular schwannoma. With the recent evolution in radiosurgery techniques involving MR imaging guidance, decreased single doses in SRS, and fractionation of radiation dose in SRT, the probabilities of vestibular schwannoma progression and cranial nerve toxicity are approximately equal. Even in the case of visual field deficit after radiation therapy for a pituitary macroadenoma (for which the probability of tumor mass progression is only 5%-10%), the cause of the deficit is more likely to be progressive tumor than radiation-induced neuropathy. Consequently, diagnosis of a late-term radiation complication must be made only after verifying that the tumor has not progressed.
颅底肿瘤放疗所致的急性毒性通常在治疗结束后的数天至数周内自行消退。长期并发症在放疗后数月至数年出现,且通常不可逆。将慢性毒性的发生概率控制在可接受水平的需求决定了肿瘤放疗剂量的上限。因此,慢性毒性的威胁影响了放疗控制颅底肿瘤的能力。采用图像引导的适形放疗技术,可使接受高剂量辐射的正常组织体积最小化,并精确控制特定结构的剂量,从而降低长期并发症的发生概率。这种适形技术可在维持慢性毒性风险可接受水平的同时,通过向肿瘤输送更高剂量的辐射来提高肿瘤控制率。慢性放射毒性所致症状与肿瘤进展引起的症状难以区分。在大多数全身放疗治疗肿瘤的病例中,放疗数月后出现的症状多为肿瘤复发所致,而非放射毒性。显著的例外是垂体腺瘤放疗后出现的垂体激素功能障碍,以及听神经瘤放射外科治疗后出现的颅神经病变。随着近期放射外科技术的发展,包括磁共振成像引导、立体定向放射治疗(SRS)单次剂量降低以及立体定向放疗(SRT)分次照射,听神经瘤进展和颅神经毒性的发生概率大致相等。即使在垂体大腺瘤放疗后出现视野缺损的情况下(肿瘤进展的概率仅为5%-10%),视野缺损更可能是肿瘤进展而非放射性神经病变所致。因此,只有在确认肿瘤未进展后,才能诊断为晚期放射并发症。